Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has hired Dr. Richard A. Rosenbloom (M.D. & Ph.D.) as its new Chief Medical Officer (CMO). Richard has been an advisor to Carbiotix since 2019 and starting in May will assist the Company with CMO duties, product development, regulatory affairs, pharmacovigilance, safety and medical affairs. Richard has decades of experience working in the United States as a CMO, Medical Director and Director of Medical Affairs for both pharmaceutical and clinical research companies. As the new CMO, Richard will support the Company's activities regarding the market launch of CarbiAXOS and ramping up the efforts concerning medical food co-interventions and therapeutic co-treatments.
Kristofer Cook, CEO of Carbiotix, comments
"It gives me pleasure to announce that Carbiotix has hired Dr. Richard Rosenbloom as Chief Medical Officer. Richard has been an advisor to the Company since 2019 and has been instrumental in guiding our product development activities. Having Richard join us as CMO will help support the market launch of CarbiAXOS as a nutraceutical ingredient in the US, and guide our work related to medical foods and therapeutic products. Like with our CFO Henrik Ljung, Richard will join us on a part-time consultancy basis, thus providing a cost-effective solution for the Company today, with an option to allocate more time in the future if needed.
Richard will assist Carbiotix with a range CMO duties, in addition to helping with product development, regulatory affairs, pharmacovigilance, safety and medical affairs. Moreover, he will be a vital mentor and colleague for our regulatory and scientific staff. Richard's CV is very impressive working as Chief Medical Officer for Synergy Research, Medical Director for Sanwa Pharmaceuticals, Director of Medical Affairs for Asta Medica Pharmaceuticals (directing international clinical drug trials in diabetes complications, pain and cancer), and Medical Director of Biotrax Clinical Research (a contract research organization directing studies in diabetes complications and rheumatoid arthritis). I think Richard's background will help us enormously in our current study with CarbiAXOS and metformin in diabetes, and future development work related to medical foods and therapeutics."
Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.